We provide you with 20 years of free, institutional-grade data for KTRA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KTRA. Explore the full financial landscape of KTRA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Kintara Therapeutics, Inc(NASDAQ:KTRA) 
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant...
Website: https://www.kintara.com/
Founded: 2009
CEO: Saiid Zarrabian
Sector: Manufacturing
Industry: Polish and Other Sanitation Good Manufacturing
The information provided in this report about KTRA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.